Meredith Y Smith

Title(s)Adjunct Associate Professor
SchoolUSC School of Pharmacy
vCardDownload vCard

    Collapse Bibliographic 
    Collapse publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Implementation Science for Effective Risk Management of Medicines: A Call for Global Action. Drug Saf. 2026 Jul 30. Smith MY, Bahri P, Darko DM, Dodoo ANO, Inoubli A, Morrato EH, Perera C, Pal S. PMID: 42533200.
      View in: PubMed   Mentions:    Fields:    
    2. Teratogenic Risk Impact Mitigation (TRIM): Development of Explicit Criteria to Facilitate Decisions Regarding Teratogenic Risk Mitigation Strategies. Drug Saf. 2025 Dec; 48(12):1387-1397. Ewig CLY, Wang Y, Smolinski NE, Toyserkani GA, LaCivita C, Lackey L, Eggers S, Sahin L, Abu-Rustum RS, Bateman BT, Berard A, Chambers CD, Choby B, Conover EA, Greene MF, Hernández-Díaz S, Jamieson DJ, Obican SG, Polifka JE, Roussos-Ross K, Sheffield JS, Lavigne SV, Zimmermann EM, Laffan SB, DeLise AM, Gilsenan AW, Hammad TA, Hampp C, Hardy JR, Knox CA, Shields K, Smith MY, Sobel RE, Tassinari MS, Maro JC, Rasmussen SA, Winterstein AG. PMID: 40762949; PMCID: PMC12605566.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    3. Using Mixed Methods to Evaluate Risk Minimisation Programs in Europe and the USA: An Innovative Blueprint. Drug Saf. 2025 Jul; 48(7):821-838. Smith MY, Davis R, Bahri P, Saragoussi D, Nguyen V, Toyserkani GA, Hamilton A. PMID: 40075031; PMCID: PMC12174294.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    4. The Reporting Recommendations Intended for Pharmaceutical Risk Minimization Evaluation Studies: Standards for Reporting of Implementation Studies Extension (RIMES-SE). Drug Saf. 2024 Jul; 47(7):655-671. Smith MY, Morrato EH, Mora N, Nguyen V, Pinnock H, Winterstein AG. PMID: 38478350; PMCID: PMC11182855.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    5. The use of implementation science theories, models, and frameworks in implementation research for medicinal products: A scoping review. Health Res Policy Syst. 2024 Jan 29; 22(1):17. Smith MY, Gaglio B, Anatchkova M. PMID: 38287407; PMCID: PMC10823700.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    6. Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternatives. Front Psychol. 2023; 14:1062830. Oliveri S, Lanzoni L, Veldwijk J, de Wit GA, Petrocchi S, Janssens R, Schoefs E, Smith MY, Smith I, Nackaerts K, Vandevelde M, Louis E, Decaluwé H, De Leyn P, Declerck H, Petrella F, Casiraghi M, Galli G, Garassino MC, Girvalaki C, Huys I, Pravettoni G. PMID: 37425173; PMCID: PMC10325723.
      View in: PubMed   Mentions: 10  
    7. Patients as research partners in preference studies: learnings from IMI-PREFER. Res Involv Engagem. 2023 Apr 07; 9(1):21. Smith MY, Janssens R, Jimenez-Moreno AC, Cleemput I, Muller M, Oliveri S, Simons G, Strammiello V, Huys I, Falahee M. PMID: 37029449; PMCID: PMC10080166.
      View in: PubMed   Mentions: 12  
    8. Improving the Safety of Medicines via Digital Technology: An Assessment of the Scope and Quality of Risk Minimization Websites in the United States and United Kingdom. Drug Saf. 2022 03; 45(3):259-274. Smith MY, Frise S, Feron J, Marshall R. PMID: 35247194; PMCID: PMC8933380.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    9. Opportunities and Challenges of Web-Based and Remotely Administered Surveys for Patient Preference Studies in a Vulnerable Population. Patient Prefer Adherence. 2021; 15:2509-2517. Oliveri S, Lanzoni L, Petrocchi S, Janssens R, Schoefs E, Huys I, Smith MY, Smith IP, Veldwijk J, de Wit GA, Pravettoni G. PMID: 34848947; PMCID: PMC8613941.
      View in: PubMed   Mentions: 10  
    10. The role of epidemiologists in communicating SARS-CoV-2 evidence: a call for adopting standards. Int J Epidemiol. 2021 11 10; 50(5):1410-1415. Smith MY, Bahri P, Gaudino JA, Moreira RS, Danyluk GM, Palevsky SL. PMID: 34179978; PMCID: PMC8344488.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsPHPublic Health
    11. Key Determinants of Health-Related Quality of Life Among Advanced Lung Cancer Patients: A Qualitative Study in Belgium and Italy. Front Pharmacol. 2021; 12:710518. Janssens R, Arnou R, Schoefs E, Petrocchi S, Cincidda C, Ongaro G, Oliveri S, Smith MY, Louis E, Vandevelde M, Nackaerts K, Pravettoni G, Huys I. PMID: 34630085; PMCID: PMC8494945.
      View in: PubMed   Mentions: 6  
    12. Patient Preferences for Lung Cancer Treatments: A Study Protocol for a Preference Survey Using Discrete Choice Experiment and Swing Weighting. Front Med (Lausanne). 2021; 8:689114. Monzani D, Petrocchi S, Oliveri S, Veldwijk J, Janssens R, Bailo L, Smith MY, Smith I, Schoefs E, Nackaerts K, Vandevelde M, Louis E, Decaluwé H, De Leyn P, Declerck H, Katz EG, Petrella F, Casiraghi M, Durosini I, Galli G, Garassino MC, de Wit GA, Pravettoni G, Huys I. PMID: 34409049; PMCID: PMC8365300.
      View in: PubMed   Mentions: 12  
    13. What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences. Front Pharmacol. 2021; 12:602112. Petrocchi S, Janssens R, Oliveri S, Arnou R, Durosini I, Guiddi P, Louis E, Vandevelde M, Nackaerts K, Smith MY, Galli G, de Marinis F, Gianoncelli L, Pravettoni G, Huys I. PMID: 33746750; PMCID: PMC7970036.
      View in: PubMed   Mentions: 9  
    14. Risk Management for the 21st Century: Current Status and Future Needs. Drug Saf. 2021 04; 44(4):409-419. Mouchantaf R, Auth D, Moride Y, Raine J, Han SY, Smith MY. PMID: 33565024; PMCID: PMC7994212.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    15. Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients. Front Public Health. 2021; 9:622154. Durosini I, Janssens R, Arnou R, Veldwijk J, Smith MY, Monzani D, Smith I, Galli G, Garassino M, Katz EG, Bailo L, Louis E, Vandevelde M, Nackaerts K, de Wit GA, Pravettoni G, Huys I. PMID: 33634069; PMCID: PMC7900128.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    16. The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies. Pharmacoepidemiol Drug Saf. 2020 12; 29(12):1532-1539. Radawski CA, Hammad TA, Colilla S, Coplan P, Hornbuckle K, Freeman E, Smith MY, Sobel RE, Bahri P, Arias AE, Bennett D. PMID: 33146901.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    17. Quantitative Benefit-Risk Assessment: State of the Practice Within Industry. Ther Innov Regul Sci. 2021 03; 55(2):415-425. Smith MY, van Til J, DiSantostefano RL, Hauber AB, Marsh K. PMID: 33111177; PMCID: PMC7864811.
      View in: PubMed   Mentions: 9     Fields:    
    18. Quality of Reporting on the Evaluation of Risk Minimization Programs: A Systematic Review. Drug Saf. 2020 05; 43(5):427-446. Russell AM, Morrato EH, Lovett RM, Smith MY. PMID: 32020558.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    19. The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products. Drug Saf. 2018 Apr; 41(4):389-401. Smith MY, Russell A, Bahri P, Mol PGM, Frise S, Freeman E, Morrato EH. PMID: 29218682; PMCID: PMC5878197.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansPHPublic Health
    20. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization. Drug Saf. 2016 09; 39(9):779-85. Smith MY, Benattia I. PMID: 27098248; PMCID: PMC4982890.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    21. Integrating risk minimization planning throughout the clinical development and commercialization lifecycle: an opinion on how drug development could be improved. Ther Clin Risk Manag. 2015; 11:339-48. Morrato EH, Smith MY. PMID: 25750537; PMCID: PMC4348129.
      View in: PubMed   Mentions: 5  
    22. Advancing the field of pharmaceutical risk minimization through application of implementation science best practices. Drug Saf. 2014 Aug; 37(8):569-80. Smith MY, Morrato E. PMID: 25005707; PMCID: PMC4134476.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    23. Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance. Drug Saf. 2013 Dec; 36(12):1129-49. Banerjee AK, Okun S, Edwards IR, Wicks P, Smith MY, Mayall SJ, Flamion B, Cleeland C, Basch E, Patient-Reported Outcomes Safety Event Reporting (PROSPER) Consortium. PMID: 24092596; PMCID: PMC3834161.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    Meredith's Networks
    Concepts (50)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (2)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-40-gb10dcd06 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.